June 16, 2020
Updates from CLIC
The use of the Clear Impact Scorecard has provided a foundation for hubs to work with the Results Based Accountability framework to gain insight on the performance of their metrics. As we transition to CMI 2.0, and begin to identify consortium-wide benchmarks and goals, we are transitioning to a new tool. NOTE: Hubs will continue to use Clear Impact Scorecard for their 2020 CMI data submissions.
CM-PRISM is a REDCap instrument. REDCap has historically shown flexibility in its reporting capacity and many across the consortium are familiar with its functionality. We expect that this system will be fully implemented and functional for August 2021 CM data submissions.
News from around the CTSA Program Consortium
Hosted by the University of Minnesota Clinical and Translational Science Institute, the Biostats4you website was developed to serve medical and public health researchers and professionals who wish to learn more about biostatistics. The site contains carefully selected and vetted training materials especially suited for a non-statistician audience. This site is being developed and maintained by members of the Biostatistics, Epidemiology and Research Design Special Interest Group (BERD SIG) of the Association for Clinical and Translational Science (ACTS).
Explore more education resources and opportunities through the CLIC Education and Career Development Gateway.
During the first in a series of webinars that launched this past April, Sege welcomed more than 100 participants to learn about the research being conducted via community engagement programs within the clinical and translational science centers at Boston University, University of Massachusetts, Tufts University, and Harvard Catalyst.
Faculty and investigators at each university are at work addressing and solving problems that impact communities directly, including health equity, evidence-based public health policies, and healthcare resources and staffing. These community engagement programs are at the core of clinical and translational science centers throughout the U.S. like Harvard Catalyst, which are funded by the NIH’s National Center for Advancing Translational Science (NCATS). In addition to community engagement initiatives, each center works to promote and accelerate clinical and translational research by providing access to training, resources, data tools, and best practices for investigators.
“Community engagement allows us and our community partners to understand the ways in which possible responses, policies, and programs would impact different groups. With strong community partnerships, we’ve been able to quickly get a sense of what’s happening on the ground during this pandemic, explained Karen Emmons, PhD, faculty lead for Harvard Catalyst’s Community Engagement program.
Watch COVID-19 Research Community Forum here.
ICYMI: News from the Science & Research World
To understand who’s dying of COVID-19, look to social factors like race more than preexisting diseases
A new county-level analysis of COVID-19 in the United States by researchers at the MIT Sloan School of Management has found that race may be just as important a factor as age in estimating a person’s risk of dying from the disease.
Even after accounting for income, health insurance coverage, rates of diabetes and obesity, and public transit use, the study found that the higher percentage of Black residents of a county, the higher its death rate from COVID-19. “The causal mechanism has to be something else,” said applied economist Chris Knittel, the study’s senior author. “If I were a public official, I’d be looking at differences in the quality of insurance, conditions such as chronic stress, and systemic discrimination.